148 related articles for article (PubMed ID: 36679862)
1. A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV.
Cheng SH; Lien CE; Hsieh SM; Cheng CY; Liu WD; Lo CL; Ko WC; Chen YH; Huang CT; Chang HT; Hwang SJ; Wang NC; Liu MC; Lee YL; Tai IC; Estrada JAG; Lin TY; Lee WS
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679862
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
3. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.
Hsieh SM; Liu WD; Huang YS; Lin YJ; Hsieh EF; Lian WC; Chen C; Janssen R; Shih SR; Huang CG; Tai IC; Chang SC
EClinicalMedicine; 2021 Aug; 38():100989. PubMed ID: 34222848
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.
Waits A; Chen JY; Cheng WH; Yeh JI; Hsieh SM; Chen C; Janssen R; Lien CE; Lin TY
Int J Infect Dis; 2022 Nov; 124():21-26. PubMed ID: 36049700
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial.
Liu LT; Chiu CH; Chiu NC; Tan BF; Lin CY; Cheng HY; Lin MY; Lien CE; Chen C; Huang LM
NPJ Vaccines; 2022 Dec; 7(1):165. PubMed ID: 36526640
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222.
Cheng SH; Lin YC; Chen CP; Cheng CY
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298566
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.
Chen CJ; Yang LY; Chang WY; Huang YC; Chiu CH; Shih SR; Huang CG; Huang KA
Nat Commun; 2022 Sep; 13(1):5466. PubMed ID: 36115850
[TBL] [Abstract][Full Text] [Related]
10. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901.
Estrada JA; Cheng CY; Ku SY; Hu HC; Yeh HW; Lin YC; Chen CP; Cheng SH; Janssen R; Lin IF
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632411
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
[TBL] [Abstract][Full Text] [Related]
14. Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine.
Lin YJ; Lin MY; Chuang YS; Liu LT; Kuo TY; Chen C; Ganesan S; Fattom A; Bitko V; Lien CE
Sci Rep; 2022 Jul; 12(1):11369. PubMed ID: 35790783
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
19. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV.
Chun HM; Milligan K; Agyemang E; Ford N; Rangaraj A; Desai S; Wilder-Smith A; Vitoria M; Zulu I
Open Forum Infect Dis; 2022 Nov; 9(11):ofac579. PubMed ID: 36438620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
